acetaminophen has been researched along with Intermittent Claudication in 2 studies
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
Intermittent Claudication: A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To test the analgesic efficacy of oxymorphone hydrochloride (OH) and propoxyphene/acetaminophen (PA) for patients with neurogenic claudication associated with lumbar spinal stenosis." | 9.20 | A Randomized, Double-blind, Placebo-Controlled Crossover Trial of Oxymorphone Hydrochloride and Propoxyphene/Acetaminophen Combination for the Treatment of Neurogenic Claudication Associated With Lumbar Spinal Stenosis. ( Chowdhry, AK; Dworkin, RH; Frazer, ME; Gewandter, JS; Markman, JD; McDermott, MP; Murray, NM; Pilcher, WH; Rast, SA; Tomkinson, EJ; Walter, KA, 2015) |
| "To test the analgesic efficacy of oxymorphone hydrochloride (OH) and propoxyphene/acetaminophen (PA) for patients with neurogenic claudication associated with lumbar spinal stenosis." | 5.20 | A Randomized, Double-blind, Placebo-Controlled Crossover Trial of Oxymorphone Hydrochloride and Propoxyphene/Acetaminophen Combination for the Treatment of Neurogenic Claudication Associated With Lumbar Spinal Stenosis. ( Chowdhry, AK; Dworkin, RH; Frazer, ME; Gewandter, JS; Markman, JD; McDermott, MP; Murray, NM; Pilcher, WH; Rast, SA; Tomkinson, EJ; Walter, KA, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ammendolia, C | 1 |
| Stuber, K | 1 |
| Tomkins-Lane, C | 1 |
| Schneider, M | 1 |
| Rampersaud, YR | 1 |
| Furlan, AD | 1 |
| Kennedy, CA | 1 |
| Markman, JD | 1 |
| Gewandter, JS | 1 |
| Frazer, ME | 1 |
| Murray, NM | 1 |
| Rast, SA | 1 |
| McDermott, MP | 1 |
| Chowdhry, AK | 1 |
| Tomkinson, EJ | 1 |
| Pilcher, WH | 1 |
| Walter, KA | 1 |
| Dworkin, RH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Physical Activity in the Elderly Spine Patient[NCT04079894] | 206 participants (Actual) | Observational [Patient Registry] | 2019-06-26 | Completed | |||
| Self-Management to Improve Walking Ability in Degenerative Lumbar Spinal Stenosis: the Evaluation of Four Novel Strategies.[NCT02592642] | 104 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Lumbar Stenosis Outcomes Research II: Opana IR Versus Placebo and Active Control (Darvocet) for the Treatment of Walking Impairment in Lumbar Spinal Stenosis: A Double-Blind Randomized, Cross-Over Trial[NCT00652093] | Phase 4 | 24 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Removal of Darvocet from US market) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects were instructed to walk on the treadmill and to tell the research coordinator to stop testing when they reached the point at which they typically would need to stop and sit down, or until 15 minutes had elapsed. At defined intervals (every 30 seconds) subjects were asked what their pain level was according to the NRS. The area under the curve of present pain intensity is the total area combined for the amount of time the subject walked. (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale * minutes (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 76.0 |
| Opana Then Placebo Then Darvocet | 95.7 |
| Placebo Then Opana Then Darvocet | 95.0 |
| Placebo Then Darvocet Then Opana | 86.4 |
| Darvocet Then Opana Then Placebo | 123.3 |
| Darvocet Then Placebo Then Opana | 79.6 |
Subjects were instructed to walk on the treadmill and to tell the research coordinator to stop testing when they reached the point at which they typically would need to stop and sit down, or until 15 minutes had elapsed. At defined intervals subjects were asked what their pain level was according to the NRS. When the subject reached their maximum distance, they were asked their NRS score. This was recorded as final pain intensity. (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 4.6 |
| Opana Then Placebo Then Darvocet | 6.6 |
| Placebo Then Opana Then Darvocet | 6.2 |
| Placebo Then Darvocet Then Opana | 6.7 |
| Darvocet Then Opana Then Placebo | 8.0 |
| Darvocet Then Placebo Then Opana | 7.1 |
The mBPI is a series of questions that rates the severity and impact of pain on daily function. The questionnaire is made up of 4 pain severity items using the NRS scale, and seven 11-point pain interference scales (0 indicating no interference and 10 indicating complete interference). For the interference score, a total score of 10 indicates pain completely interferes with activities. (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 3.7 |
| Opana Then Placebo Then Darvocet | 4.2 |
| Placebo Then Opana Then Darvocet | 2.7 |
| Placebo Then Darvocet Then Opana | 4.3 |
| Darvocet Then Opana Then Placebo | 6.2 |
| Darvocet Then Placebo Then Opana | 2.8 |
The ODI is a set of 10 questions each with five choices (maximum score of 5 points per question) designed to determine how back pain has affected the ability to manage everyday life (pain intensity, personal care, lifting, walking, sitting, standing, sleeping, social life, traveling, and change positions). A score of 0 indicates no disability and total score of 50 would indicate 100% disability. (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 37.9 |
| Opana Then Placebo Then Darvocet | 98.4 |
| Placebo Then Opana Then Darvocet | 38.0 |
| Placebo Then Darvocet Then Opana | 44.1 |
| Darvocet Then Opana Then Placebo | 37.0 |
| Darvocet Then Placebo Then Opana | 29.7 |
Subjects were asked to rate their low back pain according to the PGA. PGA is the impact of disease activity. PGA was measured on a 5-point scale, where 1=very good, 2=good, 3=fair, 4=poor, and 5=very poor. (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 2.8 |
| Opana Then Placebo Then Darvocet | 2.8 |
| Placebo Then Opana Then Darvocet | 3.1 |
| Placebo Then Darvocet Then Opana | 2.6 |
| Darvocet Then Opana Then Placebo | 3.3 |
| Darvocet Then Placebo Then Opana | 2.6 |
After the subject completed the treadmill test they were asked to immediately return to the seated position. At this point a timer was started. When the subjects pain level returned to baseline (level of pain subject felt in a seated position before walking) the time was stopped. This was recorded as recovery time. Maximum recovery time is 15 minutes. (NCT00652093)
Timeframe: study visit
| Intervention | minutes (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 1.10 |
| Opana Then Placebo Then Darvocet | 1.50 |
| Placebo Then Opana Then Darvocet | 2.02 |
| Placebo Then Darvocet Then Opana | 1.58 |
| Darvocet Then Opana Then Placebo | 2.15 |
| Darvocet Then Placebo Then Opana | 1.57 |
The RMDQ consists of 24 yes/no statements about activity limitations due to back pain. These questions center on movement, ambulation, and self-care activities. Positive (yes) answers each contribute 1 point to cumulative score with total scores ranging from 0 (no disability) to 24 (severely disabled). (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 12.8 |
| Opana Then Placebo Then Darvocet | 15.3 |
| Placebo Then Opana Then Darvocet | 13.2 |
| Placebo Then Darvocet Then Opana | 15.2 |
| Darvocet Then Opana Then Placebo | 13.7 |
| Darvocet Then Placebo Then Opana | 7.4 |
The SSS is a series of questions asking about symptom severity, physical function, and satisfaction. The physical function section is a series of 5 questions (maximum 4 points per question) and asks to rate function for each question based on comfortably, sometimes with pain, always with pain, no functional ability. The total score (max=20) is divided by five. The maximum score for the physical function section (max=4) indicates no ability to function. (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 2.5 |
| Opana Then Placebo Then Darvocet | 2.5 |
| Placebo Then Opana Then Darvocet | 2.6 |
| Placebo Then Darvocet Then Opana | 2.6 |
| Darvocet Then Opana Then Placebo | 2.6 |
| Darvocet Then Placebo Then Opana | 2.2 |
The SSS is a series of questions asking about symptom severity, physical function, and satisfaction. The symptom severity section is a set of 7 questions (maximum score is 5 points per question) and asks to rate pain for each question based on no pain, mild, moderate, severe or very severe pain. The total score (maximum=35) is added up and divided by seven. The maximum score for the symptom severity section (score=5) indicates very severe symptom severity. (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 2.6 |
| Opana Then Placebo Then Darvocet | 2.9 |
| Placebo Then Opana Then Darvocet | 3.2 |
| Placebo Then Darvocet Then Opana | 3.2 |
| Darvocet Then Opana Then Placebo | 3.6 |
| Darvocet Then Placebo Then Opana | 2.9 |
Using the Numeric Rating Scale (NRS) (0=no pain, 10=worst pain imaginable)the time to first symptoms (Tfirst) with a NRS score greater than or equal to 4 (moderate pain level), with treadmill ambulation was measured. Patients were excluded from the trial if there pain at rest was greater than or equal to 4/10. (NCT00652093)
Timeframe: study visit
| Intervention | minutes (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 1.73 |
| Opana Then Placebo Then Darvocet | 3.02 |
| Placebo Then Opana Then Darvocet | 3.93 |
| Placebo Then Darvocet Then Opana | 2.65 |
| Darvocet Then Opana Then Placebo | 0.83 |
| Darvocet Then Placebo Then Opana | 5.43 |
Subjects were instructed to walk on the treadmill and to tell the research coordinator to stop testing when they reached the point at which they typically would need to stop and sit down, or until 15 minutes had elapsed. When the subject reached their maximum distance, the treadmill testing was stopped. This was recorded as total distance based on number of minutes and seconds walked. Minutes was converted to meters based on calculation of defined speed of the treadmill. (NCT00652093)
Timeframe: study visit
| Intervention | meters (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 266.6 |
| Opana Then Placebo Then Darvocet | 249.5 |
| Placebo Then Opana Then Darvocet | 177.9 |
| Placebo Then Darvocet Then Opana | 290.1 |
| Darvocet Then Opana Then Placebo | 160.8 |
| Darvocet Then Placebo Then Opana | 294.8 |
The VAS asked subjects to place a mark indicative of their low back pain during the past day on a 100mm line, with 0mm representing no pain and 100mm representing extreme pain. (NCT00652093)
Timeframe: study visit
| Intervention | units on a scale (Mean) |
|---|---|
| Opana Then Darvocet Then Placebo | 51.3 |
| Opana Then Placebo Then Darvocet | 57.9 |
| Placebo Then Opana Then Darvocet | 56.2 |
| Placebo Then Darvocet Then Opana | 46.7 |
| Darvocet Then Opana Then Placebo | 63.3 |
| Darvocet Then Placebo Then Opana | 55.1 |
1 review available for acetaminophen and Intermittent Claudication
| Article | Year |
|---|---|
What interventions improve walking ability in neurogenic claudication with lumbar spinal stenosis? A systematic review.
Topics: Acetaminophen; Amines; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Bone Densi | 2014 |
What interventions improve walking ability in neurogenic claudication with lumbar spinal stenosis? A systematic review.
Topics: Acetaminophen; Amines; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Bone Densi | 2014 |
What interventions improve walking ability in neurogenic claudication with lumbar spinal stenosis? A systematic review.
Topics: Acetaminophen; Amines; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Bone Densi | 2014 |
What interventions improve walking ability in neurogenic claudication with lumbar spinal stenosis? A systematic review.
Topics: Acetaminophen; Amines; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Bone Densi | 2014 |
1 trial available for acetaminophen and Intermittent Claudication
| Article | Year |
|---|---|
A Randomized, Double-blind, Placebo-Controlled Crossover Trial of Oxymorphone Hydrochloride and Propoxyphene/Acetaminophen Combination for the Treatment of Neurogenic Claudication Associated With Lumbar Spinal Stenosis.
Topics: Acetaminophen; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Analgesics, Opioid; Cross-Over Stu | 2015 |